For the millions living with autosomal dominant polycystic kidney disease (ADPKD), the gold-standard drug tolvaptan carries an uncomfortable burden: dose-limiting polyuria that forces patients to wake repeatedly at night and constrains therapeutic dosing. A newly identified intracellular signaling axis may offer a way to keep tolvaptan's cyst-slowing benefits while taming its most disruptive side effect.
The central discovery is that intracellular urate — not vasopressin — can independently drive aquaporin-2 (AQP2) water channels to the apical membrane of renal collecting duct cells. When two transporters act in concert — GLUT9b importing urate apically and ABCG2 failing to export it — intracellular urate accumulates, activating phosphodiesterase-4, which degrades cyclic AMP and subsequently engages AMP-activated protein kinase (AMPK). This AMPK activation redirects internalized AQP2 through a post-endocytic apical trafficking route, concentrating water channels at the luminal surface independently of the classical vasopressin V2 receptor–cAMP–PKA cascade. Blocking ABCG2 with probenecid in both wild-type and Pkd1RC/RC mice substantially blunted tolvaptan-induced urine output without undermining cyst growth suppression. A Phase 2 clinical trial in tolvaptan-treated ADPKD patients confirmed that probenecid reduced urine volume and nocturia frequency in humans.
This work matters beyond nephrology. AMPK is a master metabolic sensor implicated in aging, mTOR suppression, and cellular stress responses — its role in governing membrane trafficking of a water channel adds a metabolic dimension to renal physiology that was largely unappreciated. The urate-AMPK-AQP2 axis also positions gout-adjacent biology at the kidney tubule as therapeutically actionable territory. Critically, probenecid is a decades-old, well-characterized uricosuric agent, which shortens the translational runway considerably. Limitations include the Phase 2 trial's modest scale and the need for longer-term human data confirming that probenecid co-administration doesn't erode tolvaptan's kidney-protective efficacy over years. Still, the mechanistic coherence across cell models, mouse disease models, and human trial data makes this finding unusually robust for a single publication — potentially paradigm-shifting for how clinicians manage tolvaptan tolerability.